| Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study S Lonial, HC Lee, A Badros, S Trudel, AK Nooka, A Chari, AO Abdallah, ... The lancet oncology 21 (2), 207-221, 2020 | 759 | 2020 |
| Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study S Lonial, HC Lee, A Badros, S Trudel, AK Nooka, A Chari, AO Abdallah, ... Cancer 127 (22), 4198-4212, 2021 | 131 | 2021 |
| Socioeconomic and racial disparity in chimeric antigen receptor T cell therapy access N Ahmed, M Shahzad, E Shippey, R Bansal, MU Mushtaq, ... Transplantation and Cellular Therapy 28 (7), 358-364, 2022 | 81 | 2022 |
| Clinical characteristics, molecular profile and outcomes of myeloid sarcoma: a single institution experience over 13 years V Kaur, A Swami, D Alapat, AO Abdallah, P Motwani, LF Hutchins, ... Hematology 23 (1), 17-24, 2018 | 66 | 2018 |
| Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial S Lonial, R Popat, C Hulin, S Jagannath, A Oriol, PG Richardson, T Facon, ... The Lancet Haematology 9 (11), e822-e832, 2022 | 63 | 2022 |
| Patterns of central nervous system involvement in relapsed and refractory multiple myeloma A Abdallah, S Atrash, Z Shahid, M Jameel, M Grazziutti, S Apewokin, ... Clinical Lymphoma Myeloma and Leukemia 14 (3), 211-214, 2014 | 63 | 2014 |
| Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: a case report and review of literature AO Abdallah, A Herlopian, R Ravilla, M Bansal, S Chandra-Reddy, ... Journal of Oncology Pharmacy Practice 22 (3), 537-542, 2016 | 50 | 2016 |
| Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study PG Richardson, HC Lee, AO Abdallah, AD Cohen, P Kapoor, ... Blood cancer journal 10 (10), 106, 2020 | 49 | 2020 |
| Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma SZ Usmani, J Sawyer, A Rosenthal, M Cottler-Fox, J Epstein, S Yaccoby, ... Blood, The Journal of the American Society of Hematology 121 (23), 4753-4757, 2013 | 46 | 2013 |
| Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019 N Balmaceda, M Aziz, VT Chandrasekar, B McClune, S Kambhampati, ... BMC cancer 21, 1-11, 2021 | 35 | 2021 |
| CAR-T treatment for hematological malignancies S Atrash, K Bano, B Harrison, AO Abdallah Journal of Investigative Medicine 68 (5), 956-964, 2020 | 34 | 2020 |
| Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs … S Lonial, HC Lee, A Badros, S Trudel, AK Nooka, A Chari, AOA Abdallah, ... Journal of Clinical Oncology 38 (15_suppl), 8536-8536, 2020 | 32 | 2020 |
| Efficacy and safety of CD34+ stem cell boost for delayed hematopoietic recovery after BCMA directed CAR T-cell therapy JA Davis, DW Sborov, W Wesson, K Julian, AO Abdallah, JP McGuirk, ... Transplantation and Cellular Therapy 29 (9), 567-571, 2023 | 25 | 2023 |
| Reporting of postprotocol therapies and attrition in multiple myeloma randomized clinical trials: a systematic review GR Mohyuddin, K Koehn, AO Abdallah, AM Goodman, V Prasad JAMA Network Open 4 (4), e218084-e218084, 2021 | 23 | 2021 |
| Fixed duration therapy with daratumumab, carfilzomib, lenalidomide and dexamethasone for high risk smoldering multiple myeloma-results of the ascent trial SK Kumar, M Alsina, B Laplant, AZ Badros, AO Abdallah, R Abonour, ... Blood 140 (Supplement 1), 1830-1832, 2022 | 20 | 2022 |
| Aggressive smoldering curative approach evaluating novel therapies (ASCENT): a phase 2 trial of induction, consolidation and maintenance in subjects with high risk smoldering … SK Kumar, AO Abdallah, AZ Badros, B Laplant, B Dhakal, M Alsina, ... Blood 136, 35-36, 2020 | 19 | 2020 |
| Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: a systematic review GR Mohyuddin, K Koehn, AO Abdallah, D W Sborov, SV Rajkumar, ... American journal of hematology 96 (6), 690-697, 2021 | 18 | 2021 |
| A phase II study of venetoclax in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma C Gasparetto, KM Bowles, AO Abdallah, L Morris, G Mander, S Coppola, ... Clinical Lymphoma Myeloma and Leukemia 21 (11), 775-784, 2021 | 16 | 2021 |
| Successful treatment of Bing-Neel syndrome using intrathecal chemotherapy and systemic combination chemotherapy followed by BEAM auto-transplant: a case report and review of … AO Abdallah, S Atrash, J Muzaffar, M Abdallah, M Kumar, F Van Rhee, ... Clinical Lymphoma Myeloma and Leukemia 13 (4), 502-506, 2013 | 15 | 2013 |
| Safety and efficacy of teclistamab in patients with relapsed/refractory multiple myeloma: a real-world experience D Dima, JA Davis, N Ahmed, X Jia, A Sannareddy, H Shaikh, L Shune, ... Transplantation and cellular therapy 30 (3), 308. e1-308. e13, 2024 | 14 | 2024 |
